<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015899</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068571</org_study_id>
    <secondary_id>PBTC-003</secondary_id>
    <secondary_id>SPRI-P02201</secondary_id>
    <nct_id>NCT00015899</nct_id>
  </id_info>
  <brief_title>SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors</brief_title>
  <official_title>Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      cancer cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in&#xD;
      treating children with recurrent or progressive brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxicity of SCH 66336 in children with&#xD;
           recurrent or progressive brain tumors.&#xD;
&#xD;
        -  Estimate the maximum tolerated dose of this drug in these patients.&#xD;
&#xD;
        -  Describe the pharmacokinetics of this drug with and without dexamethasone in these&#xD;
           patients.&#xD;
&#xD;
        -  Investigate the efficacy of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral SCH 66336 twice daily. Treatment repeats every 4 weeks for a total of&#xD;
      26 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-6 patients receive escalating doses of SCH 66336 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose at which it is predicted that 20% of&#xD;
      patients may experience dose-limiting toxicity. An additional 6 patients are treated at the&#xD;
      determined MTD.&#xD;
&#xD;
      Patients are followed within 30 days of the last administration of the study drug and then&#xD;
      for up to 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities of SCH 66336 in children and adolescents with refractory CNS cancers</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of SCH 66336</measure>
    <time_frame>Four weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of SCH 66336</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response to SCH 66336</measure>
  </secondary_outcome>
  <enrollment type="Actual">53</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lonafarnib</intervention_name>
    <other_name>SCH 66336</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent or progressive (refractory) brain tumors&#xD;
&#xD;
               -  Histologic confirmation waived for brainstem gliomas&#xD;
&#xD;
          -  Bone marrow involvement allowed if transfusion independent&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  21 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Lansky 60-100% OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal&#xD;
&#xD;
          -  SGPT and SGOT less than 2.5 times normal&#xD;
&#xD;
          -  Albumin greater than 3 g/dL&#xD;
&#xD;
          -  PT/PTT no greater than 120% upper limit of normal&#xD;
&#xD;
          -  No overt hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal OR&#xD;
&#xD;
          -  Glomerular filtration rate greater than 70 mL/min&#xD;
&#xD;
          -  No overt renal disease&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No overt cardiac disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No overt pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Neurologic deficits allowed if stable for at least 1 week prior to study&#xD;
&#xD;
          -  More than 3rd percentile weight for height&#xD;
&#xD;
          -  Able to swallow pills&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No known or suspected allergy to poloxamer 188, croscarmellose sodium, silicon&#xD;
             dioxide, or magnesium stearate I&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 10 weeks after&#xD;
             study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 6 months since prior bone marrow transplantation&#xD;
&#xD;
          -  More than 1 week since prior growth factors&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent dexamethasone allowed if on stable dose for at least 1 week prior to study&#xD;
&#xD;
          -  Concurrent oral contraceptives or other hormonal contraceptive methods allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 6 weeks since prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  More than 3 months since prior craniospinal radiotherapy (more than 24 Gy) or total&#xD;
             body irradiation&#xD;
&#xD;
          -  More than 2 weeks since prior focal radiotherapy for symptomatic metastatic sites&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsant drugs&#xD;
&#xD;
          -  No other concurrent anticancer or experimental drug therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark W. Kieran, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0372</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20;25(21):3137-43.</citation>
    <PMID>17634493</PMID>
  </results_reference>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 13, 2009</last_update_submitted>
  <last_update_submitted_qc>October 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>James M. Boyett/PBTC Operations and Biostatistics Center Executive Director</name_title>
    <organization>Pediatric Brain Tumor Consortium</organization>
  </responsible_party>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>childhood spinal cord neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

